Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for stubborn Crohn's fistulas: cell therapy trial offers second chance

NCT ID NCT07629245

First seen Jun 11, 2026 · Last updated Jun 17, 2026 · Updated 3 times

Summary

This study tests the safety of injecting a patient's own fat-derived cells (stromal vascular fraction) combined with tiny skin grafts to treat anal fistulas that haven't healed with standard care in Crohn's disease. It includes 25 adults who didn't respond to a previous similar treatment. The main goal is to check for infections, incontinence, or other side effects over 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • APHM hopital NORD

    RECRUITING

    Marseille, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.